Teva Pharmaceutical Industries Ltd (TEVA) Short Interest Down 9.1% in March

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) was the recipient of a significant decline in short interest during the month of March. As of March 29th, there was short interest totalling 59,397,239 shares, a decline of 9.1% from the March 15th total of 65,322,254 shares. Currently, 5.9% of the shares of the stock are sold short. Based on an average trading volume of 10,761,075 shares, the short-interest ratio is currently 5.5 days.

NYSE:TEVA opened at $17.84 on Wednesday. Teva Pharmaceutical Industries has a 52 week low of $10.85 and a 52 week high of $33.82. The company has a current ratio of 0.86, a quick ratio of 0.58 and a debt-to-equity ratio of 1.91. The firm has a market capitalization of $18,354.63, a price-to-earnings ratio of 4.54, a price-to-earnings-growth ratio of 1.57 and a beta of 0.67.

How to Become a New Pot Stock Millionaire

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.14. The firm had revenue of $5.46 billion for the quarter, compared to the consensus estimate of $5.29 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The company’s quarterly revenue was down 15.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.38 EPS. research analysts predict that Teva Pharmaceutical Industries will post 2.3 EPS for the current fiscal year.

In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 5,050 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $19.68, for a total transaction of $99,384.00. Following the transaction, the executive vice president now owns 44,517 shares of the company’s stock, valued at $876,094.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 10,734 shares of company stock worth $204,795 over the last ninety days. Corporate insiders own 7.10% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 16.9% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 45,983 shares of the company’s stock valued at $871,000 after buying an additional 6,642 shares during the period. Xact Kapitalforvaltning AB purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $243,000. Meitav Dash Investments Ltd. purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $5,017,000. MetLife Investment Advisors LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $1,335,000. Finally, Hoylecohen LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $954,000. Hedge funds and other institutional investors own 58.22% of the company’s stock.

A number of equities analysts have weighed in on the company. Credit Suisse Group set a $23.00 price objective on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research note on Wednesday, April 4th. ValuEngine raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 2nd. Royal Bank of Canada reissued a “hold” rating and set a $16.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Monday, March 26th. Vetr lowered Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating and set a $14.71 price objective on the stock. in a research note on Monday, March 26th. Finally, Jefferies Group assumed coverage on Teva Pharmaceutical Industries in a research note on Tuesday, March 20th. They set a “hold” rating and a $19.00 price objective on the stock. Eleven investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $19.67.

COPYRIGHT VIOLATION WARNING: “Teva Pharmaceutical Industries Ltd (TEVA) Short Interest Down 9.1% in March” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://weekherald.com/2018/04/18/teva-pharmaceutical-industries-ltd-teva-short-interest-down-9-1-in-march.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply